Recommendations for genetic testing to reduce the incidence of anthracycline‐induced cardiotoxicity

AIMS: Anthracycline‐induced cardiotoxicity (ACT) occurs in 57% of treated patients and remains an important limitation of anthracycline‐based chemotherapy. In various genetic association studies, potential genetic risk markers for ACT have been identified. Therefore, we developed evidence‐based clin...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Br J Clin Pharmacol
Главные авторы: Aminkeng, Folefac, Ross, Colin J. D., Rassekh, Shahrad R., Hwang, Soomi, Rieder, Michael J., Bhavsar, Amit P., Smith, Anne, Sanatani, Shubhayan, Gelmon, Karen A., Bernstein, Daniel, Hayden, Michael R., Amstutz, Ursula, Carleton, Bruce C.
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley and Sons Inc. 2016
Предметы:
Reviews
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5338111/
https://ncbi.nlm.nih.gov/pubmed/27197003
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13008
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы